ホンダ タカフミ   HONDA Takafumi
  本田 隆文
   所属   医学部 医学科(附属八千代医療センター)
   職種   助教
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Pathomechanism of infantile traumatic brain injury with a biphasic clinical course and late reduced diffusion evaluated by MR spectroscopy.
掲載誌名 正式名:Journal of the neurological sciences
略  称:J Neurol Sci
ISSNコード:18785883/0022510X
掲載区分国外
出版社 Elsevier B.V.
巻・号・頁 466,pp.123228
著者・共著者 Madoka Yasukohchi†, Taku Omata*, Kenta Ochiai, Kentaro Sano, Yuka Murofushi, Sho Kimura, Nanako Takase, Takafumi Honda, Kumi Yasukawa, Jun-ichi Takanashi
発行年月 2024/11
概要 BACKGROUND:Infantile traumatic brain injury (TBI) with a biphasic clinical course and late reduced diffusion (TBIRD) has recently been reported as a distinct type of TBI in infancy. However, the pathological and prognostic factors of TBIRD remain unknown. We aimed to compare patients with and without TBIRD and evaluate the pathomechanism of TBIRD using magnetic resonance spectroscopy (MRS).METHODS:Ten Japanese patients with TBI were admitted to our hospital and underwent MRS between September 2015 and September 2022 (age range, 3-15 months; median age, 8.5 months). TBIRD was diagnosed in six patients. MRS data were compared among patients with TBIRD, patients without TBIRD, and controls. Neurological prognosis was classified into grades 1 (normal) to 3 (severe).RESULTS:In patients with TBIRD, MRS revealed an increase in the glutamine (Gln) level on days 3-29, which subsequently became close to normal. The degree of Gln elevation in the non-TBIRD group was smaller (117-158 % of controls) than that in the TBIRD group (210-337 %) within 14 days. MRS in the TBIRD group showed decreased N-acetyl aspartate (NAA) concentrations. The degree of NAA decrease was more prominent in grade 3 than in grades 1 and 2. NAA levels in the non-TBIRD group were almost normal.CONCLUSIONS:Patients with TBI and markedly elevated Gln levels on MRS may develop TBIRD. Neuro-excitotoxicity is a possible pathological mechanism of TBIRD. Decreased NAA levels may be useful for predicting the prognosis of patients with TBIRD.
DOI 10.1016/j.jns.2024.123228
PMID 39278172